AbbVie: Still Expensive Despite The Great M&A Acumen
…
152,880€
1,08%
Echtzeit-Aktienkurs ABBVIE
Bid:
Ask:
Nachrichten zur ABBVIE Aktie
AbbVie shares higher following ‘overdone’ reaction to CVS move to replace top-selling arthritis drug
Abbvie Inc (NYSE:ABBV) shares recovered in the early afternoon Thursday after dipping 3% in after hours trade the evening prior…
AbbVie in pact with Umoja to develop CAR-T cell therapies
…
Abbvie shares down as CVS moves to replace top selling arthritis drug with cheaper alternatives
Abbvie Inc (NYSE:ABBV) shares fell after hours on Wednesday after CVS Health Corp announced it will remove Humira, a leading rheumatoid arthritis...…
AbbVie: Kursziel gesenkt
San Francisco (www.aktiencheck.de) - Rating-Update:
Die Analysten von Wells Fargo Advisors bekräftigen das Rating "overweight" für die Aktie von AbbVie Inc.…
AbbVies Recent ImmunoGen Acquisition Looks Brilliant: Heres Why
…
AbbVies Recent ImmunoGen Acquisition Looks Brilliant: Heres Why
The acquisition fills an immediate need with some extras to boot.…
AbbVie Vs. GSK: Dual Dominance In Pharma
…
Global Biologics Drug Discovery Market Analysis, 2023-2033: Dominated by AbbVie, Amgen, AstraZeneca, and Pfizer
Dublin, Dec. 19, 2023 (GLOBE NEWSWIRE) -- The "Biologics Drug Discovery Market - A Global and Regional Analysis,…
Sorry, Santa: AbbVie Shows ‘Naughty’ Can Be Profitably Nice (For Some)
AbbVies "patent thicket" strategy and aggressive drug pricing tactics have made it a prominent example of pharma finagling. But the…
Global Myasthenia Gravis Treatment Market Forecast and Trends 2023-2028, Featuring Profiles of AbbVie, Bausch Health, Gilead Sciences, Merck, Servier and Teva
Dublin, Dec. 18, 2023 (GLOBE NEWSWIRE) -- The "Global Myasthenia Gravis Treatment Market: Forecast and Trends" report has…
Better Income Stock: AT&T or AbbVie?
…
Better Income Stock: AT&T or AbbVie?
These two blue chips are highly prized for their top-shelf dividend programs.…
Better Income Stock: AT&T or AbbVie? @themotleyfool #stocks $T $ABBV
These two blue chips are highly prized for their top-shelf dividend programs.…
AbbVie, Amgen among firms targeted for latest Medicare inflation penalties
…
Top 5 NASDAQ Biotech Stocks of 2023
This year the NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has slowly tracked downward in response to the high volatility seen across global…
AbbVie and Big Pharma Have Floundered. How That Could Change in 2024.
…
AbbVie upgraded at Goldman Sachs on improving outlook
…
AbbVies on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?
Heres whats attracting lucrative buyout offers from big pharmaceutical companies these days.…
AbbVies on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next? @themotleyfool #stocks $ABBV $IMGN $CERE
Heres whats attracting lucrative buyout offers from big pharmaceutical companies these days.…
Pharma Stock Roundup: ABBV to Buy CERE, JNJs 2024 View, LLY & NVS Get FDA Nod
AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.…
The Zacks Analyst Blog Highlights AbbVie, NIKE, BHP Group, CME Group and Block
AbbVie, NIKE, BHP Group, CME Group and Block are included in this Analyst Blog.…
AbbVies $8.7 billion bet on Cerevel is risky but smart, analysts say By Reuters
AbbVies $8.7 billion bet on Cerevel is risky but smart, analysts say…
AbbVie to focus on smaller deals after buying spree By Reuters
AbbVie to focus on smaller deals after buying spree…
AbbVie to acquire drugmaker Cerevel Therapeutics for $8.7B
Abbvie Inc (NYSE:ABBV) announced late Wednesday an agreement to acquire neuroscience drugmaker Cerevel Therapeutics for $45 per share in cash, or…
AbbVie – Cerevel M&A deal lifts Reviva, Karuna
…
Is AbbVie Stock a Buy Now?
AbbVies business could soon become more diversified.…
Is AbbVie Stock a Buy Now? @themotleyfool #stocks $ABBV $IMGN
AbbVies business could soon become more diversified.…
Which Stock Is More Likely to Help You Retire as a Millionaire: AbbVie or Eli Lilly?
Theres no guarantee that either of these big pharma stocks can help you retire as a millionaire. But one has…
AbbVie: Der nächste heiße Übernahmekandidat
AbbVie plant eine Übernahme des Biotech-Unternehmens Cerevel Therapeutics für 8,7 Milliarden Dollar, um die neurowissenschaftliche Forschung zu stärken.…
AbbVie weiter auf Einkaufstour! Aktienanalyse
Kulmbach (www.aktiencheck.de) - AbbVie-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie des…
AbbVie mit Doppelschlag - nächste Übernahme
Der Pharma-Riese AbbVie befindet sich weiter auf Einkaufstour. Nachdem die Amerikaner bereits den AKTIONÄR-Hot-Stock Immunogen schlucken wollen, streckt die Gesellschaft…
AbbVie mit Doppelschlag – nächste Übernahme
Der Pharma-Riese AbbVie befindet sich weiter auf Einkaufstour. Nachdem die Amerikaner bereits den …
Cerevel options trading surge before AbbVie deal news raises eyebrows By Reuters
Cerevel options trading surge before AbbVie deal news raises eyebrows…
AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B
AbbVie (ABBV) offers to buy Cerevel Therapeutics (CERE) for $8.7 billion. The acquisition will strengthen AbbVies neuroscience pipeline.…
AbbVie to buy drug developer Cerevel for $8.7 billion By Reuters
AbbVie to buy drug developer Cerevel for $8.7 billion…
AbbVie to buy drug developer Cerevel for $8.7 billion
…
Übernahme von Botox-Hersteller gibt AbbVie Schub
Frankfurt (Reuters) - Der US-Pharmakonzern AbbVie profitiert von einer hohen Nachfrage nach seinem Blockbuster-Medikament Humira und der Übernahme des Botox-Herstellers…
Agentur - Boehringer und AbbVie in Gesprächen über Krebs-Allianz
Bangalore (Reuters) - Deutschlands zweitgrößter Pharmakonzern Boehringer Ingelheim steht einem Agenturbericht zufolge vor einer umfassenden Partnerschaft bei Krebs-Therapien mit dem…